Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
To control for potential Type I errors due to multiple comparisons, the BenjaminiHochberg procedure was applied to adjust the p -values, thereby controlling the false discovery rate
GLP-1 response varies across patients based on variants in GIPR, FTO, MC4R, and TCF7L2
receives compensation from and holds equity in Corner Therapeutics, Larkspur Biosciences, MindImmune Therapeutics and Neumora Therapeutics
PC12 cells in the A+ NAM group presented the highest degree of senescence and apoptosis following NAM treatment (Liu et al., 2023)
US$ 24.39
US$ 26.31
US$ 29.39
US$ 24.11
